CPT code 76390 designates magnetic resonance spectroscopy (MRS), an advanced diagnostic imaging technique that measures the chemical composition and metabolism of tissues. MRS supplements conventional MRI by providing metabolic and biochemical information used in assessing brain disorders, tumor malignancy, and metabolic diseases of muscle and nervous tissue. Nationally, MRS is an important tool for diagnostic precision in neurology and oncology and can influence care planning and further diagnostic testing.

Key payers addressed in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical indications and service context, typical sites of service, and the common payer landscape for MRS billing. The publication summarizes benchmarking and coverage themes relevant to CPT code 76390, highlights policy and coding considerations that affect reimbursement and claims processing, and provides clinical context on when MRS is used alongside MRI.

This briefing is intended for national audiences including clinicians, billing professionals, and policy analysts seeking concise information on CPT code 76390, its clinical role, and payer coverage patterns. Data not provided in the input (such as specific coverage policies, utilization metrics, or associated taxonomies and ICD-10 codes) are noted as unavailable.